

FINANCIAL STATEMENTS (UNAUDITED)

For the 1st quarter ended 30th September, 2025



THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,

Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 September 2025

		Amount in Taka	
		30 September 2025	30 June 2025
Notes			
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04.A	4,894,249,647	4,701,323,681
Capital Work-In-Progress	05.1.A	2,634,972,738	2,655,519,636
Right-of-Use Assets	05.2	2,166,629,161	1,932,358,746
Advances, Deposits & Prepayments	10.A.1	26,871,578	33,072,711
Financial Assets	06.A	22,423,325	33,715,070
		43,352,844	46,657,518
Current Assets :			
Financial Assets	08.A	2,949,210,308	2,845,250,397
Inventories	08.2	22,500,000	22,500,000
Trade and Other Receivables	09.A	1,849,278,955	1,808,087,123
Advances, Deposits & Prepayments	10 A.1	195,082,186	196,052,607
Cash & Cash Equivalents	11.A	541,712,462	503,707,520
		340,636,705	314,903,147
TOTAL ASSETS		7,843,459,954	7,546,574,078
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital	12	4,215,799,823	3,997,848,260
Tax Holiday Reserve	13	4,145,153,987	3,926,901,664
FVOCI Reserve	14	312,436,270	312,436,270
Retained Earnings	15.A	4,392,110	4,392,110
Non Controlling Interest	15.B	(18,518,537)	(15,544,331)
		3,846,844,144	3,625,617,615
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16.A	1,086,604,447	1,072,158,461
Employee Benefit Obligations	17.A	991,135,998	974,705,376
Deferred Tax Liabilities	19.A	1,077,018	990,546
		94,391,431	96,462,538
Current Liabilities:			
Short Term Finance	20.A	2,541,055,685	2,476,567,357
Current Portion of Long Term Finance	21	1,077,364,608	953,683,239
Lease Liabilities	17.B	89,584,391	119,445,855
Trade and Other Payables	22 A	16,888,140	23,798,698
Unclaimed Dividend	22.B	728,292,978	842,289,127
Provision for Corporate Tax	23.A	39,941,661	42,104,508
		588,983,906	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		7,843,459,954	7,546,574,078
Net Assets Value (NAV) Per Share		31 A	132.67
			125.69


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)
For the 1st quarter ended 30 September 2025

Amount in Taka			
	Notes	From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
REVENUE	24.A	3,716,673,149	2,755,941,856
Cost of goods sold	24.1	(2,176,471,586)	(1,634,912,878)
GROSS PROFIT		1,540,201,563	1,121,028,978
OPERATING EXPENSES		(1,193,920,288)	(943,892,474)
Administrative expenses	25.A	(69,896,894)	(59,132,074)
Selling & Distribution expenses	26.A	(1,124,023,394)	(884,760,399)
OPERATING PROFIT		346,281,276	177,136,504
Financial charges	34.A	(26,706,687)	(18,601,698)
Other income		9,448,212	8,395,428
Profit before WPPF & welfare fund		329,022,801	166,930,234
Workers' P.P. fund & welfare fund	27.A	(16,099,695)	(10,560,429)
PROFIT BEFORE TAX		312,923,106	156,369,805
Income tax expenses	28.A	(91,997,337)	(71,457,455)
NET PROFIT AFTER TAX		220,925,769	84,912,349
Profit/(Loss) Attributable to:			
Owner of the Company		221,226,529	84,634,869
Non-controlling interest	35.01	(300,760)	277,480
		<u>220,925,769</u>	<u>84,912,349</u>
Other Comprehensive Income:			
Change in FVOCI Financial Assets	29	(3,304,674)	5,234,049.99
Related Deferred tax		330,467	(523,405.00)
Total other comprehensive income for the period, net of tax		<u>(2,974,207)</u>	<u>4,710,644.99</u>
Total comprehensive income for the period		217,951,562	89,622,994
Total Comprehensive income Attributable to:			
Owner of the Company		218,252,323	89,345,514
Non-controlling interest		(300,760)	277,480
		<u>217,951,562</u>	<u>89,622,994</u>
Earnings Per Share (EPS)	30.A	7.08	2.72
Number of Shares used to Compute EPS		31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka.
11 November 2025.


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2025

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other comprehensive Income-2024-25	-	-	(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the period 30 June 2024 (Cash 63.00%)				(196,834,850)	-	(196,834,850)
Issued during the year					35,000,000	35,000,000
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,625,617,614	70,946,596	3,997,848,260
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2025			(2,974,207)	221,226,529	(300,760)	217,951,562
Balance as at 30 September 2025	312,436,270	4,392,110	(18,518,539)	3,846,844,144	70,645,836	4,215,799,822

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2024

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,367	3,055,816,151
Statement of profit or loss and other comprehensive Income-2023-24		-	(6,344,369)	670,522,122	828,351	665,006,104
Dividend for the period 30 June 2023 (Cash 60.00%)				(187,461,762)	-	(187,461,762)
Issue during the year						-
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2024			4,710,645	84,634,869	277,480	89,622,995
Balance as at 30 September 2024	312,436,270	4,392,110	(3,900,076)	3,273,897,983	36,157,199	3,622,983,488


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka .
11 November 2025.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the 1st quarter ended 30 September 2025

	Amount in Taka	
	From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
Cash Flows From Operating Activities:		
Received from revenue and others	3,673,093,767	2,656,865,997
Payment for operation, expenses & others	(3,454,296,015)	(2,293,385,224)
Miscellaneous income	301,460	398,030
Cash generated from operations	219,099,212	363,878,803
Income tax paid	(22,296,605)	(43,035,574)
Payment for Financial charges	(26,155,287)	(17,467,887)
Net cash generated from operating activities	170,647,320	303,375,342
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(255,717,208)	(197,195,565)
Acquisition of financial assets	-	65,747,266
Dividend Received/ IBBL-MPB	-	1,869,684
Received from bank deposits	-	1,565,917
Net cash used in investing activities	(255,717,208)	(128,012,698)
Cash Flows From Financing Activities:		
Payment of dividend	(2,162,847)	(993,557)
Long term finance received/(paid) from bank (Net)	16,430,621	67,647,912
Short term finance received/(paid) from bank (Net)	93,819,905	(299,290,499)
Net cash from financing activities	108,087,679	(232,636,144)
Increase/(decrease) in cash and cash equivalents	23,017,791	(57,273,500)
Opening cash and cash equivalents	314,903,147	365,229,893
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	2,715,767	2,436,302
Closing cash and cash equivalents	340,636,705	310,392,695
NOCFPS (Note 32.A)	5.46	9.71


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 September 2025

		Amount in Taka	
		30 September 2025	30 June 2025
ASSETS:			
Non-Current Assets:		4,860,822,275	4,710,090,479
Property, Plant and Equipment	04	2,407,029,304	2,431,653,536
Capital Work-In-Progress	05.1	1,342,225,753	1,155,822,173
Right of Use Assets	05.2	26,871,578	33,072,711
Financial Assets	06	14,352,844	17,657,518
Advances, Deposits & Prepayments	10.1	22,173,325	33,715,070
Investment in Subsidiary	07	1,048,169,470	1,038,169,470
Current Assets :		2,568,696,827	2,424,153,681
Financial assets	08	22,500,000	22,500,000
Inventories	08.1	1,634,464,578	1,603,775,311
Trade and Other Receivables	09	188,198,398	187,596,187
Advances, Deposits & Prepayments	10.1	467,139,241	429,600,396
Cash & Cash Equivalents	11	256,394,611	180,681,788
TOTAL ASSETS		<u>7,429,519,102</u>	<u>7,134,244,160</u>
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		4,144,781,562	3,932,383,056
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(18,518,537)	(15,544,331)
Retained Earnings	15	3,846,471,719	3,631,099,007
LIABILITIES:			
Non-Current Liabilities:		856,008,657	848,925,369
Long Term Finance	16	762,200,895	753,223,072
Employee Benefit Obligations	17	1,077,018	990,546
Deferred Tax Liabilities	18	92,730,744	94,711,750
Current Liabilities:		2,428,728,883	2,352,935,736
Short Term Finance	20	1,071,333,267	933,771,898
Current Portion of Long Term Finance	21	89,584,391	119,445,855
Lease Liabilities	17.B	16,888,140	23,798,698
Trade and Other Payable	22	665,285,448	775,229,847
Unclaimed Dividend	22.B	39,941,661	42,104,508
Provision for Corporate Tax	23	545,695,976	458,584,929
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		<u>7,429,519,102</u>	<u>7,134,244,160</u>
Net Assets Value (NAV) Per Share		31	125.86


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)
For the 1st quarter ended 30 September 2025

Amount in Taka			
	Notes	From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
CONTINUING OPERATION			
REVENUE	24	3,314,047,063	2,543,805,611
Cost of goods sold	24.B	(1,950,954,106)	(1,499,078,964)
GROSS PROFIT		1,363,092,957	1,044,726,647
OPERATING EXPENSES		(1,029,959,602)	(810,986,405)
Administrative expenses	25	(54,957,161)	(49,663,286)
Selling & Distribution expenses	26	(975,002,441)	(761,323,119)
OPERATING PROFIT		333,133,356	233,740,241
Financial charges	34	(26,706,687)	(18,601,698)
Other income		9,448,212	6,630,460
Profit before WPPF & welfare fund		315,874,881	221,769,003
Workers' P.P. fund & welfare fund	27	(15,041,661)	(10,560,429)
PROFIT BEFORE TAX		300,833,220	211,208,574
INCOME TAX EXPENSES	28	(85,460,508)	(69,149,780)
NET PROFIT AFTER TAX		215,372,712	142,058,794
Other Comprehensive Income:			
Change in FVOCI Financial Assets	29	(3,304,674)	5,234,050
Related Deferred tax		330,467	(523,405)
Total other comprehensive income for the period, net of tax		(2,974,207)	4,710,645
Total comprehensive income for the period		212,398,506	146,769,439
Earnings Per Share (EPS)	30	6.89	4.55
Number of Shares used to Compute EPS		31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2025

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other comprehensive Income-2024-25			(6,933,611)	660,162,024	653,228,413
Dividend for the period 30 June, 2024 (Cash -63.00%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,631,099,008	3,932,383,056
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2025			(2,974,207)	215,372,712	212,398,506
Balance as at 30 September 2025	312,436,270	4,392,110	(18,518,539)	3,846,471,720	4,144,781,562


STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2024

Amount in Taka


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other comprehensive Income-2023-24			(6,344,369)	655,067,965	648,723,597
Dividend for the period 30 June, 2023 (Cash -60.00%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,720)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2024			4,710,645	142,058,794	146,769,439
Balance as at 30 September 2024	312,436,270	4,392,110	(3,900,075)	3,309,830,627	3,622,758,932


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka .
11 November 2025.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS (UNAUDITED)

For the 1st quarter ended 30 September 2025

	Amount in Taka	
	From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
Cash Flows From Operating Activities:		
Received from revenue and others	3,268,895,049	2,432,614,445
Payment for operation, expenses & others	(3,053,521,792)	(2,113,878,151)
Miscellaneous income	301,460	398,030
Cash generated from continuing operations	215,674,717	319,134,324
Income tax paid	(21,296,605)	(42,222,391)
Payment for Financial charges	(26,155,287)	(17,467,887)
Net cash provided by operating activities	168,222,825	259,444,046
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(199,740,649)	(172,316,890)
Acquisition of financial assets	-	67,000,000
Investment in Subsidiary	(10,000,000)	-
Dividend Received/ IBBL-MPB	-	1,869,684
Net cash used in investing activities	(209,740,649)	(103,447,206)
Cash Flows From Financing Activities:		
Payment of dividend	(2,162,847)	(993,557)
Long term finance received/(paid) from bank (Net)	8,977,822	25,385,244
Short term finance received/(paid) from bank (Net)	107,699,905	(248,170,357)
Net cash from financing activities	114,514,880	(223,778,670)
Increase/(decrease) in cash and cash equivalents	72,997,056	(67,781,830)
Opening cash and cash equivalents	180,681,788	312,475,845
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	2,715,767	2,436,302
Closing cash and cash equivalents	256,394,611	247,130,317
NOCFPS (Note 32)	5.38	8.30


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)
For the 1st quarter ended 30 September 2025

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2024.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 11 November 2025 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2025.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 30 September 2025 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2024 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in sales revenue and profit , EPS has been increased during current period over last reporting period.

3.4 DECREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share (NOCFPS) decreased during current period over last reporting period due to increase in payment for cost & expenses & others.

3.5 INCOME TAX:

Payment of income tax increased due to increase in revenue and net profit. Advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

3.7 Other income increased during the period due to increase in revenue from toll production charge.

3.8 Payment of dividend increased due to declaration of dividend on last year's income during the reporting period.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets.

3.12 SHORT TERM FINANCE:

Short term finance increased during the period due to increase in import of raw materials under working capital financing arrangement with bank.

3.13 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

		Amount in Taka	
		30 September 2025	30 June 2025
04. PROPERTY, PLANT AND EQUIPMENT:			
Cost :			
Opening balance		4,169,069,419	3,956,915,644
Addition during the period		17,282,136	215,232,652
Disposal/Adjustment during the period		-	(3,078,877)
Closing balance		4,186,351,555	4,169,069,419
Accumulated Depreciation:			
Opening balance		1,737,415,882	1,554,782,910
Charged during the period		41,906,368	185,554,095
Disposal/Adjustment during the period		-	(2,921,123)
Closing balance		1,779,322,250	1,737,415,882
Closing balance of written Down Value (WDV)		2,407,029,304	2,431,653,536
i. The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.			
ii. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.			
04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:			
The IBN SINA Pharmaceutical Industry PLC		2,407,029,304	2,431,653,536
The IBN SINA API Industry Ltd.		147,252,082	142,245,156
The IBN SINA Polymer Industry Ltd.		2,231,416	2,288,106
The IBN SINA Natural Medicine Ltd.		78,459,936	79,332,838
		2,634,972,738	2,655,519,636
05.1 CAPITAL WORK-IN-PROGRESS			
A) Construction work-in-progress (Building)			
Opening balance		711,323,283	366,379,612
Addition during the period		67,106,570	344,943,671
Less: Transferred to PPE		-	-
		778,429,853	711,323,283
B) Machinery in transit and installation			
Opening balance		398,469,652	213,664,954
Addition during the period/year		115,351,943	310,149,835
Less: Transit closed during the period/year		-	(125,345,137)
		513,821,595	398,469,652
Other Goods-In-Transit		49,974,306	46,029,239
		1,342,225,753	1,155,822,174
i) A new building is being constructed to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC.			
ii) The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet .			
iii) Capitalisation rate used is 6%			
iv. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.			
05.1A CONSOLIDATED CAPITAL WORK-IN-PROGRESS			
A) Construction work-in-progress (Building)			
Opening balance		939,492,119	465,469,776
Addition during the period/year		106,007,782	474,022,343
Closing balance		1,045,499,901	939,492,119
B) Machinery in transit and installation			
Opening balance		946,837,388	673,427,435
Addition during the period/year		124,317,567	398,755,090
Less: Transit closed during the period/year		-	(125,345,137)
Closing balance		1,071,154,955	946,837,388
Other Goods-In-Transit		49,974,306	46,029,239
		2,166,629,161	1,932,358,746
05.2 RIGHT OF USE ASSETS:			
Opening balance		130,252,602	130,252,602
Closing balance		130,252,602	130,252,602
Accumulated Depreciation:			
Opening balance		97,179,891	72,375,357
Charged during the period		6,201,133	24,804,533
Disposal/Adjustment during the year		-	-
Closing balance		103,381,024	97,179,891
Closing balance of Written Down Value (WDV)		26,871,578	33,072,711

	Amount in Taka	
	30 September 2025	30 June 2025
06. FINANCIAL ASSETS (NON-CURRENT PORTION):		
Investment in marketable securities (FVOCI)		
Exim Bank PLC	1,520,000	2,090,000
First Security Islami Bank PLC	5,332,600	7,793,800
Shahjalal Islami Bank PLC	1,915,800	1,699,500
Al-Arafah Islami Bank PLC	1,827,735	1,849,365
Social Islami Bank PLC	764,029	1,284,958
Islami Bank Bangladesh Ltd. (IBBL) in MPB	2,992,680	2,939,895
	14,352,844	17,657,518

The above investment in marketable securities are designated as Fair Value through other comprehensive income by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income.

06.A CONSOLIDATED FINANCIAL ASSETS (NON-CURRENT PORTION):

Exim Bank PLC	1,520,000	2,090,000
First Security Islami Bank PLC	5,332,600	7,793,800
Shahjalal Islami Bank PLC	1,915,800	1,699,500
Al-Arafah Islami Bank PLC	1,827,735	1,849,365
Social Islami Bank PLC	764,029	1,284,958
Islami Bank Bangladesh Ltd. (IBBL) in MPB	2,992,680	2,939,895
Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
	43,352,844	46,657,518

07 INVESTMENT IN SUBSIDIARY

The IBN SINA API Industry Ltd.	679,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.	130,000,000	130,000,000
	1,048,169,470	1,038,169,470

- i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company.
- ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.
- iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.

08. FINANCIAL ASSETS (CURRENT PORTION):

Opening balance (Investment in MTD)	22,500,000	89,500,000
MTDR-Closed during the period	-	(67,000,000)
	22,500,000	22,500,000

08.A CONSOLIDATED FINANCIAL ASSETS (CURRENT PORTION):

Investment in MTD	22,500,000	22,500,000
	22,500,000	22,500,000

08.1 INVENTORIES:

Raw materials	672,065,057	661,133,854
Packing materials	240,936,884	230,992,875
Work-in-process	103,113,345	97,983,312
Finished goods	363,215,206	357,701,249
Physicians' samples	5,938,277	5,836,177
Pad & literature	4,248,345	4,127,335
Spares & stores	381,644	360,234
Indirect materials	466,908	463,694
Printing & stationery	404,908	393,698
Laboratory chemicals	237,528	236,318
Material in Transit	243,456,476	244,546,564
	1,634,464,578	1,603,775,310

- i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.
- ii) There is no damage goods or slow moving item in the inventory list.
- iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
- iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature changed during the period for ensuring smooth supply of products.

		Amount in Taka	
		30 September 2025	30 June 2025
08.2. CONSOLIDATED INVENTORIES:			
Raw materials		755,517,055	768,094,729
Packing materials		274,641,141	245,848,438
Work-in-process		115,759,966	111,124,876
Finished goods		445,382,570	424,409,351
Physicians' samples		8,782,414	8,481,886
Pad & literature		4,248,345	4,127,335
Spares & stores		381,644	360,234
Indirect materials		466,908	463,694
Printing & stationery		404,908	393,698
Laboratory chemicals		237,528	236,318
Material in Transit		243,456,476	244,546,564
		1,849,278,955	1,808,087,123
09. TRADE AND OTHER RECEIVABLES:			
Trade receivable (net off bad debt provision)		181,402,168	181,402,168
Receivable from provident fund (PF)		304,966	304,966
Profit receivable from MTD		3,994,182	3,391,971
Other receivable-toll charge		2,497,081	2,497,081
		188,198,398	187,596,187
09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:			
Trade receivable (net off bad debt provision)		188,285,956	189,858,588
Receivable from provident fund (PF)		304,966	304,966
Profit receivable from MTD		3,994,182	3,391,971
Inter-company receivable (The IBN SINA API Industry Ltd.)		2,497,081	
Other receivable-toll charge		-	2,497,081
		195,082,186	196,052,607
i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.			
10. ADVANCES, DEPOSITS & PREPAYMENTS :			
This is recoverable in cash or for value to be received and consists of :			
a. Advances against-			
Salary		9,724,854	5,482,341
Expenses/works/others		21,961,814	12,433,414
Depot rent		6,580,983	6,727,985
Motor cycles-to employees		42,449,345	42,143,838
Others		706,533	706,533
		81,423,529	67,494,111
b. Income tax-			
Opening balance		374,539,128	200,028,807
Addition		21,296,605	174,510,320
Adjusted during the period		-	-
		395,835,733	374,539,128
c. Deposits -			
Security money		12,053,000	21,275,544
d. Pre payments -			
Value Added Tax		304	6,683
		489,312,566	463,315,466
10.1 MATURITY ANALYSIS:			
Realisable/adjustable within one year.		467,139,241	429,600,396
Realisable/adjustable after one year.		22,173,325	33,715,070
		489,312,566	463,315,466

- i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.
- ii) Advance against works, salary and motor cycle increased during this year to meet up business needs.
- iii) Advance income tax increased during this period to meet up regulatory requirement.
- iv) Security money decreased during this year as security money was adjusted by various parties.

		Amount in Taka	
		30 September 2025	30 June 2025
10 A. CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS :			
This is recoverable in cash or for value to be received and consists of :			
a. Advances against-			
Salary		13,724,954	9,555,942
Expenses/works/others		41,248,048	31,119,648
Depot rent		6,580,983	6,727,985
Motor cycles-to employees		60,454,626	61,431,738
Others		2,573,852	2,101,636
		124,582,465	110,936,949
b. Income tax			
Opening balance		404,148,716	223,481,751
Addition		22,296,605	180,666,965
Adjusted during the period		-	-
		426,445,321	404,148,716
c. Deposits -			
Security money		13,107,697	22,330,241
d. Pre payments -			
Value Added Tax		304	6,683
		564,135,787	537,422,590
10.A.1 MATURITY ANALYSIS:			
Realisable/adjustable within one year.		541,712,462	503,707,520
Realisable/adjustable after one year.		22,423,325	33,715,070
		564,135,787	537,422,590
11. CASH & CASH EQUIVALENTS:			
a. Cash in hand		8,590,175	6,613,494
b. Cash at bank		244,264,435	170,528,294
c. Imprest cash		3,540,000	3,540,000
Closing balance		256,394,611	180,681,788
11.1 CASH AT BANKS:			
i) The bank reconciliation was performed at the period end and found in order.			
ii) Physical cash counting was taken place at the period end and no surplus or deficit was found.			
11 A. CONSOLIDATED CASH & CASH EQUIVALENTS:			
a. Cash in hand		9,329,459	7,137,453
b. Cash at bank		327,637,245	304,095,694
c. Imprest cash		3,670,000	3,670,000
Closing balance		340,636,705	314,903,147
12. SHARE CAPITAL:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each		500,000,000	500,000,000
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash		312,436,270	312,436,270
The Shareholdings consist of :			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	331	5,833,394	18.67%
General Public	12,595	11,566,921	37.02%
	12,927	31,243,627	100.00%

The distribution schedule showing the number of share holders and their share holdings as on 30.09.2025 are as follows:

Range of Holdings	Amount in Taka		
	30 September 2025	30 June 2025	
No. of Holders	Total Holdings	Percentage	
Less than 500 shares	10,095	1,807,426	5.97%
500 to 5,000 shares	2,418	3,653,317	11.36%
5,001 to 10,000 shares	186	1,377,680	4.69%
10,001 to 20,000 shares	90	1,217,103	4.73%
20,001 to 30,000 shares	27	641,461	2.98%
30,001 to 40,000 shares	17	427,553	2.00%
40,001 to 50,000 shares	21	740,313	1.83%
Above 50,000 shares	73	21,378,774	66.43%
	12,927	31,243,627	100.00%

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk. 307.30 in the Dhaka Stock Exchange Limited as at 30.09.2025 and at Tk. 305.00 in the Chittagong Stock Exchange Limited as at 30.09.2025 respectively.

13. TAX HOLIDAY RESERVE:	4,392,110	4,392,110
This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.		
14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:		
Closing market value of marketable securities	14,352,844	17,657,518
Less: Cost of marketable securities	34,928,997	34,928,997
Unrealized gain before adjustment of deferred tax	(20,576,153)	(17,271,479)
Less: Deferred tax on unrealized gain (loss)	2,057,615	1,727,148
Net unrealized gain/(loss) on marketable securities	(18,518,537)	(15,544,331)
15. RETAINED EARNINGS:		
Opening Balance	3,631,099,007	3,167,771,833
Dividend paid		(196,834,850)
Add : Net profit during the period	215,372,712	660,162,024
	3,846,471,719	3,631,099,007
15 A. CONSOLIDATED RETAINED EARNINGS:		
Opening Balance	3,625,617,615	3,189,263,114
Dividend paid	-	(196,834,850)
Add: Net profit during the period	221,226,529	633,189,350
	3,846,844,144	3,625,617,615
15 B. NON CONTROLLING INTEREST:		
The IBN SINA API Industry Ltd.	200	200
The IBN SINA Natural Medicine Ltd.	3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)	70,000,000	70,000,000
Add: Share of Profit/(Loss)	642,636	943,396
	70,645,836	70,946,596
16. LONG TERM FINANCE :		
i) From Al-Arafah Islami Bank PLC. Secured (Under Hire Purchase Shirkatul Melk-HPSM)	538,108,575	565,545,640
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma	313,676,711	307,123,287
Current maturity transferred to current liability		
iii) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Melk)	(89,584,391)	(119,445,855)
LONG TERM FINANCE - net off current maturity	762,200,895	753,223,072
i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 14.50% of profit.		
ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import capital machinery and motor vehicle under Hire Purchase Shirkatul		
iii) HPSM is repayable in 84 monthly equal installment.		
iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.		
v) The company achieved AA+ rating in long term and ST-1 for short term from Alpha credit rating Ltd.		
vi) Information regarding loan fall due after five years.		
Loan fall due from 2 to 5 years	358,739,050	377,030,427
Loan fall due from 6 to more years	403,461,845	376,192,645
	762,200,895	753,223,072
16.A CONSOLIDATED LONG TERM FINANCE :		
Al-Arafah Islami Bank PLC-Secured (The IBN SINA Pharmaceutical Industry PLC)	762,200,895	753,223,072
Al-Arafah Islami Bank PLC.-Secured (The IBN SINA API Industry Ltd.)	228,935,103	221,482,304
	991,135,998	974,705,376

		Amount in Taka	
		30 September 2025	30 June 2025
17 EMPLOYEE BENEFIT OBLIGATIONS:			
Employee Benefit Obligations represents employees gratuity recognized as liability and its the movement is given below:			
Opening Balance		990,546	1,185,180
Provision during the period		36,211,899	97,491,986
Less: Paid during the period		(36,125,427)	(97,686,620)
		1,077,018	990,546
17 A. CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		990,546	1,185,180
Provision during the period		36,211,899	137,250,512
Less: Paid during the period		(36,125,427)	(137,445,146)
		1,077,018	990,546
17 B. LEASE LIABILITIES			
Opening balance		23,798,698	50,336,979
Addition during the period		-	-
Finance charge		551,400	3,692,459
Less: Paid during the period		(7,461,958)	(30,230,740)
Closing balance		16,888,140	23,798,698
Less : transferred to current maturity		(16,888,140)	(23,798,698)
		(0)	-

i) The company has lease against its Head Office and its Depot at Mohammadpur and Mirpur, Dhaka respectively.

ii) Lease period is upto 31.10.2026

iii) Advance amount paid Tk. 11,661,000

iv) Monthly adjustment Tk. 50,000

18. DEFERRED TAX LIABILITIES

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liabilities
Property, plant and equipment	2,407,029,304	1,942,197,630	464,831,674	20.00%	92,966,335
Gratuity	37,202,446	36,125,427	1,077,019	20.00%	215,404
Lease	9,983,438	1,827,283	8,156,154	20.00%	1,631,231
Unrealized gain on marketable securities	(20,576,153)	-	(20,576,153)	10.00%	(2,057,615)
Bad Debt provision	123,050	-	(123,050)	20.00%	(24,610)
As at 30 September 2025	2,433,762,085	1,980,150,341	453,365,645		92,730,744
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,523,691,863	2,054,070,505	464,923,013		94,711,750

19. DEFERRED TAX (EXPENSES)/INCOME

Closing balance of deferred tax liability	92,730,744	94,711,750
Opening balance of deferred tax liabilities	94,711,750	99,285,702
(a) Total deferred tax expenses/(income)	(1,981,006)	(4,573,952)
Add: Deferred tax expenses related to other comprehensive income	330,467	770,401
	(1,650,539)	(3,803,551)

						Amount in Taka	
						30 September 2025	30 June 2025
19 A. CONSOLIDATED DEFERRED TAX LIABILITIES:							
Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability		
Property, plant and equipment	2,632,741,322	2,160,789,896	471,951,426	20% to 27.50%	94,806,298		
Gratuity	37,202,446	36,125,427	1,077,019		215,403		
Accrued profit on mtdr	-	-	-		-		
Lease	9,331,528	1,827,283	7,504,244	10.00%	1,451,956		
Unrealized gain on marketable securities	(20,576,153)	-	(20,576,153)		(2,057,615)		
Bad Debt provision	123,050	-	(123,050)		(24,610)		
As at 30 September 2025	2,658,822,193	2,198,742,607	459,833,487		94,391,431		
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% to 27.50%	99,530,336		
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)		
Accrued profit on mtdr	-	-	-		-		
Lease	8,813,099	12,994,333	(4,181,234)	10.00%	(870,815)		
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)		(1,727,148)		
Bad Debt provision	1,358,626	-	(1,358,626)		(271,725)		
As at 30 June 2025	2,794,797,068	2,318,370,690	471,728,033		96,462,538		
19 B. DEFERRED TAX (EXPENSES)/INCOME							
Closing balance of deferred tax liability					94,391,431		96,462,538
Opening balance of deferred tax liabilities					96,462,538		101,180,185
(a) Total deferred tax expenses					(2,071,107)		(4,717,647)
Add: Deferred tax expenses related to other comprehensive income					330,467		770,401
					(1,740,640)		(3,947,246)
20. SHORT TERM FINANCE :							
From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR/UPAS))					1,071,333,267		933,771,898
					1,071,333,267		933,771,898
i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of statement of financial position @ 14.50% of profit and 0.25% commission per quarter to be paid. ii) The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal agreement. iii) Short term loan is repayable within twelve months. iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.							
20.A CONSOLIDATED SHORT TERM FINANCE :							
a) From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities PLC (MPI/TR/UPAS))					1,071,333,267		933,771,898
b) The IBN SINA API Industry Ltd.					6,031,341		19,911,341
					1,077,364,608		953,683,239
21. LONG TERM FINANCE-CURRENT MATURITY:							
i) From Al-Arafah Islami Bank PLC-Secured (Under Hire Purchase Shirkatul Melk)					89,584,391		119,445,855
22. TRADE AND OTHER PAYABLES :							
Payable to suppliers					314,537,547		354,248,263
Provisions					135,482,894		187,977,710
Accrued expenses					145,936,525		178,532,052
Security money received from employees and others					11,332,972		11,517,972
Workers' profit participation fund & welfare fund					57,995,511		42,953,850
					665,285,448		775,229,847
22.1 PROVISIONS:							
Opening balance					187,977,710		144,607,133
Provisions made during the period/year					135,482,894		187,977,710
Provisions used during the period/year					(187,977,710)		(144,607,133)
Closing balance					135,482,894		187,977,710
i) Payable to suppliers and accrued expenses decreased this year to meetup business need. ii. Accrued expenses decreased du to payment made same bill after reporting period.							

		Amount in Taka	
		30 September 2025	30 June 2025
22 A. CONSOLIDATED TRADE AND OTHER PAYABLES :			
Payable to suppliers		352,768,943	396,181,410
Provisions		158,796,453	187,977,710
Accrued expenses		145,936,525	203,253,644
Security money received from employees and others		11,332,972	11,517,972
Workers' profit participation fund & welfare fund		59,458,086	43,358,391
		728,292,978	842,289,127
22.B UNCLAIMED DIVIDEND :			
Opening		42,104,508	39,140,597
Addition		-	196,834,850
Paid to share holders		(2,162,847)	(186,963,608)
Paid to Capital Market Stabilisation Fund		-	(6,907,331)
		39,941,661	42,104,508
22.1.2 UNCLAIMED DIVIDEND :			
Year-wise break-up of the above is as follows :			
2021-22		11,975,003	12,953,290
2022-23		14,894,690	15,606,678
2023-24		13,071,967	13,544,540
		39,941,661	42,104,508
23. PROVISION FOR CORPORATE TAX			
Opening balance		458,584,929	255,866,409
Current tax provision		87,111,047	202,718,520
		545,695,976	458,584,929
23 A. CONSOLIDATED PROVISION FOR CORPORATE TAX			
Opening balance		495,245,930	284,580,559
Prior year tax assessment adjustment		-	-
Current tax expense		93,737,976	210,665,371
		588,983,906	495,245,930

		Amount in Taka	
		From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
24. REVENUE:			
Local revenue		3,267,483,392	2,494,876,975
Export revenue		46,563,671	48,928,636
		3,314,047,063	2,543,805,611
24.A CONSOLIDATED REVENUE:			
Local revenue		3,670,109,478	2,707,013,220
Export revenue		46,563,671	48,928,636
		3,716,673,149	2,755,941,856
24.B COST OF GOODS SOLD :			
Materials		1,585,534,517	1,177,304,491
Factory Overhead		331,796,015	287,414,044
Depreciation		33,623,574	34,360,429
		1,950,954,106	1,499,078,964
24.1 CONSOLIDATED COST OF GOODS SOLD:			
Materials		1,759,461,533	1,270,870,866
Factory Overhead		381,735,803	327,986,565
Depreciation		35,274,250	36,055,447
		2,176,471,586	1,634,912,878
i) Cost of materials and expenses incurred for factory overhead during the reporting period increased due to Increase in goods sold and increase in production respectively .			
25. ADMINISTRATIVE EXPENSES :			
Salary, wages & Allowances		33,977,651	32,592,499
Repairs & Maintenance		2,322,282	1,358,276
Travelling & Conveyance		1,839,085	1,297,742
Depreciation		7,098,815	6,572,248
Other Expenses		9,719,328	7,842,521
		54,957,161	49,663,286
25 A. CONSOLIDATED ADMINISTRATIVE EXPENSES :			
Salary, wages & Allowances		41,564,481	37,278,411
Repairs & Maintenance		2,452,069	1,485,912
Travelling & Conveyance		3,058,116	1,301,992
Research & Development		681,139	216,888
Fees & charges		177,374	161,712
Depreciation		9,704,681	8,880,967
Other Expenses		12,259,034	9,806,192
		69,896,894	59,132,074
i) Salary, wages & allowance increased due to increase in manpower, gratuity payment and salary revision.			
ii) Repairs & Maintenance expense increased due to increase in maintenance of fixed assets to meet business needs.			
iii) Travelling & conveyance increased during the period due to increase travel.			
iv) Research & development expense increased during this period due to meet business needs.			
26. SELLING & DISTRIBUTION EXPENSES :			
Salary, wages & Allowances		546,243,935	412,119,070
Travelling & Conveyance		1,676,722	2,008,581
Market Survey & Research and Product development		2,164,437	835,619
Field personnel expenses		154,643,819	123,357,493
Sample, Literature & Promotional Expenses		94,650,858	64,403,084
Delivery Expenses		105,114,060	98,063,787
Depreciation		7,385,113	7,995,050
Other Expenses		80,089,982	63,930,810
		991,968,927	772,713,494
Less: Expenses for INM		(16,966,486)	(11,390,375)
		975,002,441	761,323,119

Amount in Taka

26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :

	From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
Salary, wages & Allowances	639,497,900	486,209,873
Travelling & Conveyance	2,902,129	2,256,833
Market Survey & Research and Product development	2,164,437	835,619
Field personnel expenses	176,966,471	140,647,743
Sample, Literature & Promotional Expenses	105,387,371	82,313,946
Delivery Expenses	105,114,060	98,063,787
Depreciation	7,509,137	8,105,696
Other Expenses	84,481,890	66,326,902
	1,124,023,394	884,760,399

- i) Salary, wages & allowance increased due to increase in manpower, gratuity payment and salary revision.
ii) Travelling & conveyance increased during the period due to increase travel.
iii) Market Survey & Research and Product development expense increased due to increase in survey related works
iv) Field personnel expense increase due to increased of field personnel movement in order to increase sales.
v) Sample, Literature & Promotional Expenses increased in order to increase sales.
vi) Delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.
vii) Depreciation expense during the reporting period decreased due to decrease addition of fixed assets .

27. WORKERS' P.P FUND & WELFARE FUND :	15,041,661	10,560,429
27.A CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :	16,099,695	10,560,429

28. INCOME TAX EXPENSES:

Current Tax	87,111,047	65,938,262
Deferred Tax (income)/expense-note-19	(1,650,539)	3,211,518
	85,460,508	69,149,780

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	300,833,220	20.00%	60,166,644
	300,833,220	20.00%	60,166,644
Non Deductible Expenses		8.96%	26,944,403
Deferred Tax (income)/expense		-0.55%	(1,650,539)
		28.41%	85,460,508

28.A CONSOLIDATED INCOME TAX EXPENSES:

Current Tax	93,737,976	67,721,195
Deferred Tax income/(expense) (note 19 A)	(1,740,639)	3,736,260
	91,997,337	71,457,455

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	312,923,106	20% to 27.50%	65,365,723
	312,923,106	20.89%	65,365,723
Non Deductible Expenses		9.07%	28,372,253
Deferred Tax (income)/expense		-0.56%	(1,740,639)
		29.40%	91,997,337

29. CHANGE IN FVOCI FINANCIAL ASSETS:

Closing value of marketable securities	(20,576,153)	(4,333,417)
Opening value of marketable securities	(17,271,479)	(9,567,467)
	(3,304,674)	5,234,050

30. Basic earnings per share has been calculated as follows :

Earnings attributable to the Ordinary Shareholders (Net profit after tax)	215,372,712	142,058,794
Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
	6.89	4.55

		Amount in Taka	
		From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
30 A. CONSOLIDATED EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		221,226,529	84,912,349
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
		7.08	2.72
31. NET ASSETS VALUE PER SHARE (NAV) :			
Net Assets Value		4,144,781,562	3,932,383,056
Divided by number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		132.66	125.86
Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earnings.			
31 A. CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV):			
Net Assets Value		4,215,799,823	3,997,848,260
Less: Non Controlling Interest		(70,645,836)	(70,946,596)
Equity Attributable to the owners of the company		4,145,153,987	3,926,901,664
Divided by number of Ordinary Shares outstanding during the year		31,243,627	31,243,627
		132.67	125.69
32. NET OPERATING CASH FLOWS PER SHARE (NOCFPS):			
Net cash provided by operating activities		168,222,825	259,444,046
Divided by number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		5.38	8.30
32 A. CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS):			
Net cash provided by operating activities		170,647,320	303,375,342
Divided by number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		5.46	9.71
33. RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES:			
Profit before tax (PBT)		300,833,220	211,208,574
Adjustment			
Depreciation		48,107,501	48,927,727
Deferred Tax		(1,981,006)	3,211,518
Unrealized foreign exchange loss		(2,715,767)	(2,436,302)
Change In operating assets			
Increase in inventory		(30,689,267)	(148,478,377)
Increase in accounts receivables		(602,211)	25,740,695
Decrease in advances, deposits and prepayments		1,561,327	3,947,151
Increase/(decrease) in trade and other payable		(99,244,092)	42,492,297
Increase/(decrease) in retirement benefit obligation		956,411	184,281,986
Tax paid during the year		(21,296,605)	(97,393,255)
Finance charge		(26,706,687)	(12,057,969)
		168,222,825	259,444,046
34. FINANCE CHARGE:			
Finance charge for long term finance.		26,155,287	17,467,887
Finance charge for lease		551,400	1,133,811
		26,706,687	18,601,698
34.A CONSOLIDATED FINANCE CHARGE:			
Finance charge for long term finance.		26,155,287	17,467,887
Finance charge for lease		551,400	1,133,811
		26,706,687	18,601,698

34.B CONSOLIDATED WORKERS' P.P. FUND & WELFARE FUND

The IBN SINA Pharmaceutical Industry PLC
The IBN SINA Natural Medicine Ltd.

Amount in Taka	
From 1 July 2025 to 30 September 2025	From 1 July 2024 to 30 September 2024
15,041,661	10,560,429
1,058,034	-
16,099,695	10,560,429

35 RELATED PARTY DISCLOSURE:


Name of party	Relationship	Nature of transaction	Transaction		Sept' 2025	June 2025
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		10,000,000	679,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Distribution Expense	16,966,486	-	238,169,670	238,169,670
					-	-
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Lease rental		-		

35.01. NON-CONTROLLING INTEREST

The IBN SINA API Industry Ltd.
The IBN SINA Natural Medicine Ltd.
The IBN SINA Polymer Industry Ltd.

Profit Amount	NCI (%)	Net/Loss Amount
(8,344,611)	0.000050	(4.17)
14,566,499	0.001260	183
(859,827)	35.000000	(300,939)
5,362,061		(300,760)


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
11 November 2025.


Managing Director


Chairman